Trial Profile

First-in-human clinical trial of ET-101

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caveolin 1 gene therapy University of California San Diego (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; First in man

Most Recent Events

02 Dec 2022 New trial record
20 Nov 2022 According to a Forge Biologics media release, the company announced a partnership with preclinical biotech company Eikonoklastes Therapeutics that will advance ET-101 gene therapy into clinical trials for patients with ALS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com